First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or third-line treatment is often needed to better manage the disease. The CHF market is heavily genericized, and prescribers have many drugs and drug classes from which to choose, creating a high barrier to uptake for novel branded agents, such as Novartis’s Entresto and Amgen’s Corlanor. This Treatment Algorithms report offers insight into the prescribing patterns across all CHF patients in the United States.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CHF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CHF patients?
  • How have Entresto and Corlanor been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of CHF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of CHF patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Novartis, AstraZeneca, Amgen

Key drugs: SGLT-2 inhibitors, Entresto, ACE inhibitors

Table of contents

  • Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms CDA Chronic Heat Failure US March 2021
    • Treatment Algorithms CDA Chronic Heart Failure US 2021 Dashboard

Author(s): Gideon Heap

Gideon Heap, M.Sc., is a director on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at DRG, part of Clarivate. In addition to authoring several reports, he has conducted company strategy and portfolio analyses for DRG’s Company & Drug platform. He holds a master’s degree in biochemistry from the University of Nottingham.

Related Reports

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological...

View Details

Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2020

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophysiology...

View Details

Heart Failure | Disease Landscape and Forecast | G7 | 2020

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates...

View Details

Heart Failure - Geographic Focus: China - Heart Failure | China In-Depth | China

Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population...

View Details